Correlation Between Microsoft and Genmab AS

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Microsoft and Genmab AS at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Microsoft and Genmab AS into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Microsoft and Genmab AS, you can compare the effects of market volatilities on Microsoft and Genmab AS and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Microsoft with a short position of Genmab AS. Check out your portfolio center. Please also check ongoing floating volatility patterns of Microsoft and Genmab AS.

Diversification Opportunities for Microsoft and Genmab AS

0.46
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Microsoft and Genmab is 0.46. Overlapping area represents the amount of risk that can be diversified away by holding Microsoft and Genmab AS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Genmab AS and Microsoft is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Microsoft are associated (or correlated) with Genmab AS. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Genmab AS has no effect on the direction of Microsoft i.e., Microsoft and Genmab AS go up and down completely randomly.

Pair Corralation between Microsoft and Genmab AS

Given the investment horizon of 90 days Microsoft is expected to generate 0.92 times more return on investment than Genmab AS. However, Microsoft is 1.09 times less risky than Genmab AS. It trades about 0.06 of its potential returns per unit of risk. Genmab AS is currently generating about 0.0 per unit of risk. If you would invest  26,766  in Microsoft on January 20, 2024 and sell it today you would earn a total of  13,661  from holding Microsoft or generate 51.04% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy98.96%
ValuesDaily Returns

Microsoft  vs.  Genmab AS

 Performance 
       Timeline  
Microsoft 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Microsoft are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively stable technical and fundamental indicators, Microsoft is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.
Genmab AS 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Genmab AS are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of very healthy basic indicators, Genmab AS is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors.

Microsoft and Genmab AS Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Microsoft and Genmab AS

The main advantage of trading using opposite Microsoft and Genmab AS positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Microsoft position performs unexpectedly, Genmab AS can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Genmab AS will offset losses from the drop in Genmab AS's long position.
The idea behind Microsoft and Genmab AS pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Other Complementary Tools

Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Global Correlations
Find global opportunities by holding instruments from different markets
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Fundamental Analysis
View fundamental data based on most recent published financial statements
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals